Fluorouracil

Cytostatic drug which is widely used systemically (see Fluorouracil/Internal Medicine below) and locally in various forms of application and indications.

Topical in a 5% cream application for actinic keratoses and basal cell carcinomas after previous curettage (Efudix®). This treatment approach requires sufficient experience from both the therapist and the patient.

Topically used in a 0.5% concentration in combination with 10% salicylic acid for localized actinic keratoses and for field carcinogenesis with good success (Actikerall®).

Topically in a 0.5% solution in combination with 10% salicylic acid and DMSO as therapeutic agent for viral warts (Verrumal®).

Dermatitis with blistering; diffuse hair loss (in children) after prolonged local application with measurable levels of 5-fluorouracil in the blood (according to individual case reports). Transient hyperpigmentation often occurs with intralesional injections (e.g. keloids).

Efudix®^, 5-FU Hexal®, Tolak® 40 mg/g cream, Verrumal®.

1. Khandpur S et al (2003) Successful treatment of multiple premalignant and malignant lesions in arsenical keratosis with a combination of acitretin and intralesional 5-fluorouracil. J Dermatol 30: 730-734
2. Nanda S et al (2004) Intralesional 5-fluorouracil as a treatment modality of keloids. Dermatol Surgery 30: 54-57
3. Steffen C (2003) Topical 5-fluorouracil. Skinmed 2: 123-126
4. Zamiri M et al (2003) Plantar warts treated with an immune response modifier: a report of two cases. Clin Exp Dermatol 28(Suppl1): 45-47